AGI to fix Healthcare & solve disease

A deep-tech start-up incubated and co-developed by the UK Golden Triangle universities (Oxford, Cambridge, and King’s College London) that applies a proprietary form of Superintelligence—model predictive as opposed to pattern-matching—to deliver precision healthcare and predictive medicine at scale.

Predictive Superintelligence-as-a-Service

Oxford Immune Algorithmics is an AI research and product company building a future where AI, Artificial General Intelligence (AGI) and Superintelligence are used first and foremost for meaningful purposes.

We are coders, engineers, and scientists behind some widely used AI products, including some of the early technology powering Siri and Alexa, Wolfram|Alpha, which enabled those systems to answer contextual factual questions later also deployed by OpenAI as the first Retrieval-augmented Generation (RAG) plugin for ChatGPT that helps reduce LLM inaccuracies and hallucinations.

For OIA and the world’s experts in logic and computation, AGI and Superintelligence are all about optimal model prediction rather than machine emulation of human behavior—such as speech (as in chatbots).

Our founder is a world-leading pioneer in the development of methods and applications of Algorithmic Probability (AP)—the ultimate theory of prediction—applied to scientific discovery, living systems, and cell and molecular biology. AP underpins all AI, AGI, and Superintelligence and was originally introduced by the founders of computation, some of whom were advisors and supervisors to our founder.

With over 100 peer-reviewed papers in some of the most prestigious scientific journals, OIA’s AI expertise is devoted to helping solve the most pressing challenges of the human condition, from inequalities in healthcare systems (even within developed countries) to clinical staff shortages and disease burden; from antibiotic resistance to chronic inflammation to cancer.

Developed by OIA, Algocyte® is a suite of AGI-driven end-to-end solutions that enable remote and personal digital endpoints in healthcare pathways from clinic to home and from home to clinic based on regular monitoring of blood markers and lifestyle events.

With two medical device patents granted in the U.S., OIA’s Algocyte® combines medtech and AI to learn and build digital blood twins based on each user’s personal and longitudinal data. It provides a detailed representation of an individual’s current health baseline, against which deviations can be tracked and diagnostic hypotheses tested—a predictive early detection system powered by our AGI inference engine aimed at extending healthy lifespans for people.

23m+

Access to

enriched patient longitudinal records from high quality clinical data.

250K

proprietary

super accurate labelled repository of normal and pathological single-cell images for AI training purposes

100+

published

peer-reviewed papers
validating OIA’s science

Access to

120m+

diagnosis & clinical data points

1tn+

proprietary

mechanistic, explainable, and interpretable computable models and testable scientific hypotheses for disease progression

won

multiple

innovation & AI prizes beating companies such as Microsoft, Accenture, and Etihad in international competitions

Fully sponsored and produced by the highest-impact scientific journal, Nature, this video, based on our peer-reviewed publication in the same journal,  explains OIA’s causal and model-driven approach to Artificial General Intelligence.

Algocyte’s universal input devices

  • Fully end-to-end automated portable lab to monitor people’s health at home, from anaemia to infection to cancer to auto immune diseases

  • Data collection: Capable of ingesting multiple data streams from multiple types of data-generating and testing IoT devices

  • Collects & deals with multiple sources of clinical, biological and lifestyle data cross referencing one against each other

  • An open platform on which commercial & academic solutions can be developed and deployed by software and reagent updates based on light, spectral and immunofluorescence microscopy

  • Automation tools for classification and triaging of users and patients

  • AI at bedside care that enables detection of early signals for better and faster clinical responses

  • Can monitor & learn from users over time to support clinical pathways and predictive medicine

  • Advanced AI-reasoning & predictive capabilities for remote care and precision healthcare

  • Finds prescription gaps to support governments and life science companies to implement predictive population health management strategies

  • Algocyte® can help understand the dynamics of health and disease, find prescription gaps, complement at-home therapeutic solutions, enable home-driven precision medicine, and manage remote predictive care

Generative AGI diagnostics

Leading AI-driven solutions built using symbolic regressive and predictive Artificial General Intelligence are causal model-driven.

OIA’s Proprietary technology is based on years of research at Oxford, Cambridge, King’s College London, and the Karolinska Institute, which awards the Nobel Prize in Physiology or Medicine.

Built on 3 key pillars

Algocyte® is an AGI precision diagnostics platform providing proprietary quantitative risk assessment scores

Quantitative Precision

Prediction, Prevention and Early Detection

Professionals can analyse users’ results relative to personalised norms, triage, and flag concerning trends

Individualised Learning and Monitoring

The Algocyte® platform learns from each user based on a digital twin baseline and builds their personal profile allowing forecasting, prediction or diagnosing

Want to find out more?

In our downloadable PDF, we share the in-depth science behind our breakthrough product. Delve into the specifics of our leading precision & predictive platform.